TickerTalks
Browse all tickers →
TickerTalks›$MDLN
MDMDLN

Medline Inc.

Trending onWhy it's trendingX mentions rising faster than the marketBacked by solid revenue growthPrice and volume picking up
$MDLN·$35B·Medical - Instruments & Supplies·Healthcare
$39.84+3.1%YTD-7.8%1Y-5.7%
Mentions · last 7 days
2026-07-08: 22 posts2026-07-09: 18 posts2026-07-10: 12 posts2026-07-11: 10 posts2026-07-12: 21 posts2026-07-13: 49 posts2026-07-14: 26 posts158+21%
Price updated 13m ago·X counts updated 16h ago
MDMDLN
$MDLNMedline Inc.
$39.84+3.05%158 posts+21%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $MDLN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-15

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Medline is a $34.7B recent IPO (5/26 at $37) trading at $38.66 with an active plaintiff-bar investigation after 'manufacturing violation' reports — Q2 8/5 is the first real print.

Medline is a $34.7B medical-supply distributor that IPO'd 5/26 at $37 per share and now trades at $38.66 — essentially at the IPO price. Down 7.8% YTD (post-IPO), down 5.7% over twelve months. Position vs 200-day is missing (limited history). This is a fresh public company still finding its natural investor base.

  • Fundamentals reflect a scaled distribution/manufacturing operator: Q1 revenue $7.35B (+10.7% yoy), 24% gross margin (thin), 5.7% op margin, EPS $0.16 (an 11.8% beat vs $0.30 est — wait, actually beat $0.30 est to $0.33 print). FY26 consensus is $31.1B revenue and $1.51 EPS growing to $33.6B/$1.66 in 2027 — mid-single-digit topline growth on massive scale.
  • PE 28.6 is elevated for a healthcare distributor; the market is paying for the private-company-to-public-company transition premium.
  • The overhang: 7/7 HBSS 'MDLN ALERT' referenced 'undisclosed manufacturing violations and failed contamination investigations' — this is the substance behind the plaintiff-bar (Pomerantz) investigations. Real reputational risk if confirmed in Q2 disclosures.
  • 7/6 announcement: securing 1.6M+ sq ft of new distribution space in Northern California after a fire — operational disruption but recovery underway.
  • 6/2 8-K: $2.0B new senior secured notes ($1.25B at 5.0% due 2031 + $750M at 5.25% due 2033) — material debt refinancing of the private-company stack.
  • 5/26 424B4: selling stockholders offered 72.5M shares at $37 ($2.685B gross, no proceeds to company) — the secondary lock-up dynamics matter for supply.
  • Insider tape empty this window (recent IPO, limited history).
  • Structural: high float (851M — very high post-IPO), beta -0.42 (defensive), volume 0.67x 30-day norm, position 0.01 vs 50d. Wide float, quiet tape.
  • X sample empty for this window.

Next dated read is Q2 on 8/5 with consensus EPS $0.32. Any explicit response to 'manufacturing violation' allegations + updated FY guide + Northern California disruption commentary is the substance.

What to watch: Q2 print 8/5: EPS vs $0.32, revenue trend, and — critically — any explicit response to HBSS/Pomerantz 'manufacturing violation' allegations. Watch for post-IPO lock-up expirations that could bring more supply.

On the calendar: 2026-08-05 — Q2 2026 earnings (consensus EPS $0.32)

no sentiment

Read the AI verdict + X sentiment for $MDLN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Manufactures and distributes medical-surgical supplies (gloves, gowns, IV sets) directly to hospitals, surgery centers, and post-acute facilities.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $MDLN.

Medical - Instruments & Supplies · Healthcare

No material change from last week — Medline's prime vendor model wins market share as hospitals simplify sourcing, while bioprocessing component suppliers (WST, RGEN, AVTR) recover from the..

What this means for $MDLN

Neutral — Manufactures and distributes medical-surgical supplies (gloves, gowns, IV sets) directly to hospitals, surgery centers, and post-acute facilities; this business's revenue is largely decoupled from the hospital supply simplification and prime vendor consolidation trend.

Industry benchmark

8-name peer basket
+7.5%YTD
+11.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
28.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
5.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
7.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
6.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
24.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 6, 2026$0.33$0.30+11.8%
Q4 2025Feb 25, 2026$0.22$0.24-7.6%
Q3 2025Nov 4, 2025$0.31——
Next earningsWed, Aug 5·consensus EPS $0.32

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.4B+10.7%22.6%5.7%$0.16$316.0M
Q4 FY25$7.8B+21.9%24.6%5.5%$0.22$571.0M
Q3 FY25$7.1B+15.0%23.9%8.1%$0.41$535.0M
Q2 FY25$6.9B—25.1%9.1%$0.42$103.0M

Forward consensus

5-year forecast · up to 19 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$31.1B$31.0B – $31.2B$1.51$1.45 – $1.5619
FY27$33.6B$33.4B – $33.7B$1.66$1.59 – $1.7019
FY28$36.1B$36.1B – $36.1B$1.87$1.65 – $2.1018
FY29$38.7B$38.1B – $48.3B$2.11$2.06 – $2.7911
FY30$41.3B$40.7B – $51.6B$2.37$2.32 – $3.139

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+1.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 851.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.425-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellMay 28Bcp 8 Holdings Mozart Manager L.l.c.10% owner33.3M sh$1.2BSellMar 10Carlyle Group Inc.10% owner26.1M sh$1.1BSellMar 10Bcp 8 Holdings Mozart Manager L.l.c.10% owner27.9M sh$1.1B
+ 14 other (9 others · 5 conversions) in window

See when $MDLN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJul 98-K — Item 5.02: Officer or director change
AI summary

Modine Manufacturing announced that Chief Operating Officer Stephen Miller will retire on August 30, 2026, citing health reasons. Miller has been a key figure in the company's transformation toward data center thermal management and Climate Solutions. His planned departure will require Modine to identify a successor or redistribute his responsibilities among the existing leadership team. The retirement was characterized as planned and health-related rather than related to any disagreement with management or board direction.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Medline Inc. held its 2026 Annual Meeting on June 11, 2026. Shareholders voted on: (i) election of 12 director nominees; (ii) Say-on-Pay on an advisory basis; (iii) frequency of future Say-on-Pay advisory votes; and (iv) ratification of Ernst & Young LLP as auditor for fiscal 2026. The Say-on-Pay frequency vote is notable as a first-time disclosure for this recently-listed PE-backed medical supply company, reflecting standard public company compliance.

8-KMaterial agreementJun 28-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Medline's indirect subsidiaries issued $2.0B in new senior secured notes on May 28, 2026: $1.25B at 5.000% due 2031 and $750M at 5.250% due 2033, with Wilmington Trust as trustee and subsidiary guarantors. Material refinancing of Medline's private-company debt stack at fixed rates, locking in long-term financing.

424B4Prospectus supplement (offering)May 26424B4
AI summary

Selling stockholders of Medline Inc. (MDLN) offered 72,554,594 shares of Class A common stock at $37.00/share ($2.685 billion gross); Medline receives no proceeds from this secondary offering. Underwriting discounts are $0.4625/share; selling stockholders net ~$36.54/share (~$2.651B). Underwriters hold an overallotment option for 10,883,189 additional shares; delivery expected May 28, 2026. Lead underwriters include Goldman Sachs, Morgan Stanley, BofA, and JPMorgan. This is a large secondary sale with no new company dilution.

S-1Initial registrationMay 20S-1
AI summary

Medline Inc. (MDLN) filed an S-1 registration statement on May 20, 2026, initiating the registration process for an initial public offering. Medline is a Northfield, Illinois-based private healthcare supply company — one of the largest private companies in the U.S. — with CEO James Boyle. The S-1 filing marks the beginning of Medline's path to a public listing; the company had previously been taken private by a private equity consortium in 2021 for approximately $34 billion. This is a potentially large and transformative IPO for the healthcare supplies sector.

3New insider — initial holdingsMar 63
424B4Prospectus supplement (offering)Mar 6424B4
S-1Initial registrationMar 3S-1
+ 29 other (9 13Gs · 5 3s · 2 EFFECTs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLNprnewswire.com·6d agoMDLN ALERT: HBSS Probes Medline (MDLN) After Reports Reveal Undisclosed Manufacturing Violations and Failed Contamination Investigationsprnewswire.com·8d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medline Industries, Inc. - MDLNglobenewswire.com·8d agoSecuring new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern Californiagurufocus.com·9d agoSecuring new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern Californiaprnewswire.com·9d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$WST$AVTR$RGEN$QDEL$WRBY$AZTA$PLSE
Voices on X · last 7 days

No standout posts about $MDLN on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport